Hacker News Reader

The article doesn't give details, but one of the quoted authors has participated in trials testing anti-ICOS antibody alone or in combination with atezolizumab, with results presented at an ASCO meeting: https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.26...

Describes one complete response in TNBC (and 4 partial responses in TNBC and other cancers). Couldn't find a related peer-reviewed journal article on very quick search.

View on HN

I have not heard of anti-ICOS (Inducible costimulatory receptor) before. Seems specific to TME.

KY1044 with mouse models (different authors):

https://aacrjournals.org/cancerimmunolres/article/8/12/1568/...

KY1044 I think is Kymab in Cambridge:

https://www.kymab.com/pipeline/ky1044/

Yes, Sanofi licensed from Kymab. There are a few groups targeting ICOS/ICOSL to modulate immune response to tumor (either alone or in combo with PD-1, CTLA-4, etc approaches previously mentioned on HN). Here's one reasonably recent backgrounder on rationale: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7003380/

Still not clear that KY1044 really is the "experimental drug" mentioned in the linked BBC article, since as others have noted the article is pretty thin on detail.

Reply on news.ycombinator.com